The Trump administration scrapped a proposal for lowering prescription medicine prices, backing down from a policy that would have required health insurers to pass on billions of dollars in rebates they receive from drugmakers to Medicare patients.
Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.
Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.
The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.
CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.
A group of health insurers, including CVS Health Corp.’s Aetna, have teamed up with IBM Corp. to create a blockchain network aimed at cutting costs in the healthcare industry.
CVS Pharmacy unveiled an initiative in U.S. stores, labeling photos of models in the drugstore chain’s beauty aisles to make it clear whether the images had been digitally altered.
Clinical Trial Finds Formula in Merix Pharmaceutical’s RELEEV 1 Day Cold Sore Highly Active Against Herpes
Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.
Bankers are diagnosing another robust year for U.S. healthcare lending as the first two big loans of 2019 include the largest-ever tie-up in the pharmaceutical sector, and more are expected.